Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B

Chu,Weiwei; Guan,Lili; Huang,Dihua; Ren,Yuezhong; Zhou,Yan

doi:10.3892/etm.2016.3547

Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B

Authors:
- Weiwei Chu
- Lili Guan
- Dihua Huang
- Yuezhong Ren
- Yan Zhou
View Affiliations

Affiliations: Department of Cadre Health Care, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China, Department of Endocrinology and Metabolism, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China, Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Cardiovascular Medicine, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: July 26, 2016 https://doi.org/10.3892/etm.2016.3547
Pages: 1741-1749
Copyright: © Chu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Statins are HMG-CoA reductase inhibitors that are used to decrease the blood levels of low‑density lipoprotein (LDL). In addition, they have been shown to exert pleiotropic protective effects in the absence of LDL-lowering activity. The present study investigated the effects of lovastatin on global gene expression in human umbilical vein endothelial cells (HUVECs), in order to further explore its ability to protect against oxidized (ox)‑LDL‑induced cytotoxicity. HUVECs were treated with lovastatin for 2‑24 h, and gene expression patterns were analyzed using cDNA microarrays. The results suggested that numerous genes were regulated by lovastatin, including certain genes associated with cell survival, such as PTK2B, BCL2 and MAP3K3. In particular, PTK2B, which has been shown to exert anti‑apoptotic effects against ox‑LDL‑induced cell injury, was upregulated by lovastatin. Knockdown of PTK2B was able to attenuate ox‑LDL‑induced cell injury, and this was associated with decreased levels of phosphorylated‑AKT and eNOS, and inhibition of mitochondrial‑dependent apoptosis. In conclusion, the results of the present study suggested that lovastatin protects against ox-LDL-induced cell injury, potentially via the upregulation of PTK2B, which regulates the anti‑apoptosis signaling pathway.

View Figures

View References

1	Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
2	Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
3	Ganesh SK, Nass CM and Blumenthal RS: Anti-atherosclerotic effects of statins: Lessons from prevention trials. J Cardiovasc Risk. 10:155–159. 2003. View Article : Google Scholar : PubMed/NCBI
4	LaRosa JC: Statins and risk of coronary heart disease. JAMA. 283:2935–2936. 2000. View Article : Google Scholar : PubMed/NCBI
5	Clemenson ND: Statins and risk of coronary heart disease. JAMA. 283:29352000. View Article : Google Scholar : PubMed/NCBI
6	Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY and Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 328:313–318. 1993. View Article : Google Scholar : PubMed/NCBI
7	Goldstein JL and Brown MS: A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 26:161–72. 2015. View Article : Google Scholar
8	Massy ZA, Keane WF and Kasiske BL: Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction? Lancet. 347:102–103. 1996. View Article : Google Scholar : PubMed/NCBI
9	Wierzbicki AS, Poston R and Ferro A: The lipid and non-lipid effects of statins. Pharmacol Ther. 99:95–112. 2003. View Article : Google Scholar : PubMed/NCBI
10	Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1440–1445. 1998. View Article : Google Scholar : PubMed/NCBI
11	Laufs U: Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 58:719–731. 2003.PubMed/NCBI
12	Hilbert T, Poth J, Frede S, Klaschik S, Hoeft A, Baumgarten G and Knuefermann P: Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells. Biochem Pharmacol. 86:1452–1460. 2013. View Article : Google Scholar : PubMed/NCBI
13	Moncada S, Palmer RM and Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev. 43:109–142. 1991.PubMed/NCBI
14	Rabelink TJ and Luscher TF: Endothelial nitric oxide synthase: Host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol. 26:267–271. 2006. View Article : Google Scholar : PubMed/NCBI
15	Sukhova GK, Williams JK and Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 22:1452–1458. 2002. View Article : Google Scholar : PubMed/NCBI
16	Giroux LM, Davignon J and Naruszewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1165:335–338. 1993. View Article : Google Scholar : PubMed/NCBI
17	Arnaud C, Braunersreuther V and Mach F: Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med. 15:202–206. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kumai T, Matsumoto N, Koitabashi Y, Takeba Y, Oonuma S, Sekine S, Tadokoro M and Kobayashi S: Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: Candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 3:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
19	Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT and Ledet T: Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J. 360:363–370. 2001. View Article : Google Scholar : PubMed/NCBI
20	Liles WC and Kain KC: Endothelial activation and dysfunction in the pathogenesis of microvascular obstruction in severe malaria-a viable target for therapeutic adjunctive intervention. J Infect Dis. 210:163–164. 2014. View Article : Google Scholar : PubMed/NCBI
21	Alvarez De Sotomayor M, Herrera MD, Marhuenda E and Andriantsitohaina R: Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br J Pharmacol. 131:1179–1187. 2000. View Article : Google Scholar : PubMed/NCBI
22	Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 23:168–175. 2003. View Article : Google Scholar : PubMed/NCBI
23	Matthys KE and Bult H: Nitric oxide function in atherosclerosis. Mediators Inflamm. 6:3–21. 1997. View Article : Google Scholar : PubMed/NCBI
24	Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 362:801–809. 1993. View Article : Google Scholar : PubMed/NCBI
25	Noll G, Tschudi M, Nava E and Lüscher TF: Endothelium and high blood pressure. Int J Microcirc Clin Exp. 17:273–279. 1997. View Article : Google Scholar : PubMed/NCBI
26	Kita T, Brown MS and Goldstein JL: Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest. 66:1094–1100. 1980. View Article : Google Scholar : PubMed/NCBI
27	Huang TH, Peng G, Li GQ, Yamahara J, Roufogalis BD and Li Y: Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-alpha. Toxicol Appl Pharmacol. 210:225–235. 2006. View Article : Google Scholar : PubMed/NCBI
28	Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, et al: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2:ra732009. View Article : Google Scholar : PubMed/NCBI
29	Lang F, Henke G, Embark HM, Waldegger S, Palmada M, Böhmer C and Vallon V: Regulation of channels by the serum and glucocorticoid-inducible kinase - implications for transport, excitability and cell proliferation. Cell Physiol Biochem. 13:41–50. 2003. View Article : Google Scholar : PubMed/NCBI
30	Husain M, Jiang L, See V, Bein K, Simons M, Alper SL and Rosenberg RD: Am J Physiol. 272:C1947–C1959. 1997.PubMed/NCBI
31	Gadepalli R, Singh NK, Kundumani-Sridharan V, Heckle MR and Rao GN: Novel role of proline-rich nonreceptor tyrosine kinase 2 in vascular wall remodeling after balloon injury. Arterioscler Thromb Vasc Biol. 32:2652–2661. 2012. View Article : Google Scholar : PubMed/NCBI
32	Slattery ML, Lundgreen A and Wolff RK: MAP kinase genes and colon and rectal cancer. Carcinogenesis. 33:2398–2408. 2012. View Article : Google Scholar : PubMed/NCBI
33	Vogler M: Targeting BCL2-proteins for the treatment of solid tumours. Adv Med. 2014:9436482014. View Article : Google Scholar : PubMed/NCBI
34	Tse KW, Lin KB, Dang-Lawson M, Guzman-Perez A, Aspnes GE, Buckbinder L and Gold MR: Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells. Cell Immunol. 275:47–54. 2012. View Article : Google Scholar : PubMed/NCBI
35	Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E and Los M: Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
36	Nemoto S, Kobayashi T, Taguchi K, Matsumoto T and Kamata K: Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol. 301:H2383–H2394. 2011. View Article : Google Scholar : PubMed/NCBI
37	Hilbert T, Poth J, Frede S, Klaschik S, Hoeft A, Baumgarten G and Knuefermann P: Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells. Biochem Pharmacol. 86:1452–1460. 2013. View Article : Google Scholar : PubMed/NCBI
38	Wang Y, Zhou D, Phung S, Masri S, Smith D and Chen S: SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol. 25:72–82. 2011. View Article : Google Scholar : PubMed/NCBI
39	Maier G, Palmada M, Rajamanickam J, Shumilina E, Böhmer C and Lang F: Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3. Cell Physiol Biochem. 18:177–186. 2006. View Article : Google Scholar : PubMed/NCBI
40	Burdick AD, Ivnitski-Steele ID, Lauer FT and Burchiel SW: PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells. Carcinogenesis. 27:2331–2340. 2006. View Article : Google Scholar : PubMed/NCBI
41	Cao J, Chen Y, Fu J, Qian YW, Ren YB, Su B, Luo T, Dai RY, Huang L, Yan JJ, et al: High expression of proline-rich tyrosine kinase 2 is associated with poor survival of hepatocellular carcinoma via regulating phosphatidylinositol 3-kinase/AKT pathway. Ann Surg Oncol. 20(Suppl 3): S312–S323. 2013. View Article : Google Scholar : PubMed/NCBI
42	Daou GB and Srivastava AK: Reactive oxygen species mediate Endothelin-1-induced activation of ERK1/2, PKB and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic Biol Med. 37:208–215. 2004. View Article : Google Scholar : PubMed/NCBI
43	Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis. 29:2096–2105. 2008. View Article : Google Scholar : PubMed/NCBI
44	Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
45	Kugiyama K, Kerns SA, Morrisett JD, Roberts R and Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:160–162. 1990. View Article : Google Scholar : PubMed/NCBI
46	Simon BC, Cunningham LD and Cohen RA: Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 86:75–79. 1990. View Article : Google Scholar : PubMed/NCBI
47	Dimmeler S, Haendeler J, Galle J and Zeiher AM: Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury’ hypothesis. Circulation. 95:1760–1763. 1997. View Article : Google Scholar : PubMed/NCBI
48	Harada-Shiba M, Kinoshita M, Kamido H and Shimokado K: Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem. 273:9681–9687. 1998. View Article : Google Scholar : PubMed/NCBI
49	Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM and Dimmeler S: Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation. 103:2102–2107. 2001. View Article : Google Scholar : PubMed/NCBI
50	Kotamraju S, Hogg N, Joseph J, Keefer LK and Kalyanaraman B: Inhibition of oxidized low-density lipoprotein-induced apoptosis in endothelial cells by nitric oxide: Peroxyl radical scavenging as an antiapoptotic mechanism. J Biol Chem. 276:17316–17323. 2001. View Article : Google Scholar : PubMed/NCBI
51	Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, Poon RT, Man K, Wong N and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One. 6:e188782011. View Article : Google Scholar : PubMed/NCBI
52	Lim ST, Miller NL, Nam JO, Chen XL, Lim Y and Schlaepfer DD: Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 285:1743–1753. 2010. View Article : Google Scholar : PubMed/NCBI
53	Yoon H, Choi YL, Song JY, Do I, Kang SY, Ko YH, Song S and Kim BG: Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One. 9:e885872014. View Article : Google Scholar : PubMed/NCBI